Consequently, it can be expected that agonizing the PACAP binding receptors or antagonizing PAC1 could become an appropriate target for atherosclerosis treatment by reducing plaque-associated chondrogenesis and may induce the regression of the lesions. Here, ADCYAP1R1 is linked to atherosclerosis.